company background image
INO

Inovio Pharmaceuticals NasdaqGS:INO Stock Report

Last Price

US$1.94

Market Cap

US$444.3m

7D

21.3%

1Y

-79.0%

Updated

26 Jun, 2022

Data

Company Financials +
INO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

INO Stock Overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.

Inovio Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Inovio Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.94
52 Week HighUS$9.96
52 Week LowUS$1.38
Beta0.82
1 Month Change-2.51%
3 Month Change-45.66%
1 Year Change-78.98%
3 Year Change-34.01%
5 Year Change-75.26%
Change since IPO-96.71%

Recent News & Updates

Shareholder Returns

INOUS BiotechsUS Market
7D21.3%10.3%6.6%
1Y-79.0%-24.3%-18.4%

Return vs Industry: INO underperformed the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: INO underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is INO's price volatile compared to industry and market?
INO volatility
INO Average Weekly Movement14.7%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: INO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: INO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1979317Jacqueline Sheahttps://www.inovio.com

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever.

Inovio Pharmaceuticals Fundamentals Summary

How do Inovio Pharmaceuticals's earnings and revenue compare to its market cap?
INO fundamental statistics
Market CapUS$444.34m
Earnings (TTM)-US$328.33m
Revenue (TTM)US$1.60m

277.5x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INO income statement (TTM)
RevenueUS$1.60m
Cost of RevenueUS$266.17m
Gross Profit-US$264.57m
Other ExpensesUS$63.76m
Earnings-US$328.33m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.43
Gross Margin-16,507.76%
Net Profit Margin-20,485.92%
Debt/Equity Ratio4.6%

How did INO perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is INO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INO?

Other financial metrics that can be useful for relative valuation.

INO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue73.4x
Enterprise Value/EBITDA-0.4x
PEG Ration/a

Price to Book Ratio vs Peers

How does INO's PB Ratio compare to its peers?

INO PB Ratio vs Peers
The above table shows the PB ratio for INO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.3x
VXRT Vaxart
2.9x76.0%US$478.0m
BLUE bluebird bio
1.2x26.5%US$314.4m
LXRX Lexicon Pharmaceuticals
3.3x42.0%US$303.7m
VBIV VBI Vaccines
1.8x70.2%US$236.8m
INO Inovio Pharmaceuticals
1.3x40.9%US$444.3m

Price-To-Book vs Peers: INO is good value based on its Price-To-Book Ratio (1.3x) compared to the peer average (2.3x).


Price to Earnings Ratio vs Industry

How does INO's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: INO is good value based on its Price-To-Book Ratio (1.3x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is INO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate INO's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of INO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate INO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate INO's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INO's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Inovio Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


40.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INO's revenue (75% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: INO's revenue (75% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if INO's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Inovio Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-27.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: INO is currently unprofitable.

Growing Profit Margin: INO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: INO is unprofitable, and losses have increased over the past 5 years at a rate of 27% per year.

Accelerating Growth: Unable to compare INO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: INO has a negative Return on Equity (-92.47%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Inovio Pharmaceuticals's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: INO's short term assets ($399.9M) exceed its short term liabilities ($59.4M).

Long Term Liabilities: INO's short term assets ($399.9M) exceed its long term liabilities ($31.1M).


Debt to Equity History and Analysis

Debt Level: INO has more cash than its total debt.

Reducing Debt: Insufficient data to determine if INO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: INO has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 29.8% each year.


Discover healthy companies

Dividend

What is Inovio Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate INO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as INO has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Jacqueline Shea (55 yo)

0.083

Tenure

US$2,310,157

Compensation

Dr. Jacqueline E. Shea, Ph D., serves as its Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief O...


CEO Compensation Analysis

Compensation vs Market: Jacqueline's total compensation ($USD2.31M) is about average for companies of similar size in the US market ($USD2.83M).

Compensation vs Earnings: Jacqueline's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: INO's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: INO's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.


Top Shareholders

Company Information

Inovio Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Inovio Pharmaceuticals, Inc.
  • Ticker: INO
  • Exchange: NasdaqGS
  • Founded: 1979
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$444.340m
  • Shares outstanding: 229.04m
  • Website: https://www.inovio.com

Number of Employees


Location

  • Inovio Pharmaceuticals, Inc.
  • 660 West Germantown Pike
  • Suite 110
  • Plymouth Meeting
  • Pennsylvania
  • 19462
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.